Immunovant, Inc.
A clinical-stage biopharmaceutical company developing experimental antibody medicines for autoimmune diseases, where the body's own defenses attack healthy tissue. Its drug candidates, like batoclimab, work by lowering the harmful antibodies that drive these conditions. Immunovant was founded in 2018 within the Roivant Sciences family and went public in 2019 through a merger. Its name blends "immuno," for immunology, with the "-vant" suffix that Roivant gives all its specialized subsidiaries.
Bought 16.67M
Granted 174.2K
Granted 75.0K · Sold 35.8K
Granted 601.0K · Sold 14.2K
Granted 83.7K · Sold 48.5K
Granted 66.9K · Sold 60.2K
Sold 3.9K
Granted 59.2K · Sold 39.3K
Granted 22.9K · Sold 9.0K
Granted 13.9K · Sold 15.0K
Granted 210.5K · Sold 244.2K
Granted 13.9K
Granted 13.9K · Sold 2.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Roivant Sciences Ltd.Director, 10% owner · 1 transaction | +17.2% | 113.32M | — | 16.67M | — |
| Torti FrankDirector · 1 transaction | +20.9% | 1.01M | 174.2K | — | — |
| Girao TiagoChief Financial Officer · 4 transactions | +23.6% | 257.6K | 75.0K | — | 35.8K |
| Venker EricChief Executive Officer, Director · 5 transactions | — | 251.8K | 601.0K | — | 14.2K |
| Gloria MelanieChief Operating Officer · 13 transactions | +17.8% | 219.3K | 83.7K | — | 48.5K |
| Stout Jay SChief Technology Officer · 11 transactions | +6.6% | 218.4K | 66.9K | — | 60.2K |
| Geffner MichaelChief Medical Officer · 2 transactions | -1.7% | 218.0K | — | — | 3.9K |
| Van Tuyl ChristopherChief Legal Officer · 9 transactions | +23.4% | 198.4K | 59.2K | — | 39.3K |
| Pande AtulDirector · 7 transactions | +11.3% | 136.7K | 22.9K | — | 9.0K |
| Hughes Douglas J.Director · 3 transactions | -0.8% | 134.7K | 13.9K | — | 15.0K |
| Fromkin Andrew J.Director · 9 transactions | +21.6% | 131.4K | 210.5K | — | 244.2K |
| Bauer JakeDirector · 1 transaction | +55.5% | 38.9K | 13.9K | — | — |
| Susman Robert GrahamDirector · 2 transactions | +45.5% | 36.4K | 13.9K | — | 2.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +16.19M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.